Procollagen IIA mediates positive feedback control of the mouse cardiogenic transcriptional network
- PMID: 40901887
- PMCID: PMC12440608
- DOI: 10.1073/pnas.2422592122
Procollagen IIA mediates positive feedback control of the mouse cardiogenic transcriptional network
Abstract
Cardiogenesis relies on the integrated interplay between cardiac transcription factors and signaling pathways. Here, we uncover a role for type IIA procollagen (IIA), an extracellular matrix (ECM) protein encoded by an alternatively spliced Col2a1 transcript, encoding a N-terminal cysteine-rich domain, as a critical regulator in a cardiac gene regulatory feedback loop. The cysteine-rich domain of IIA protein was previously reported to interact with bone morphogenetic proteins (BMPs) and transforming growth factors-beta (TGFβ) in in vitro binding assays and acts as a BMP antagonist in amphibian embryo assays. We show that the Col2a1 gene in mice is activated in the developing heart by core cardiogenic factors (NKX2-5, GATA4, MEF2, and SRF) via cis-regulatory enhancer elements. IIA loss (ΔIIA) in mice results in depletion of Isl1- and Nkx2-5-expressing progenitors, causing outflow tract defects resembling disrupted BMP/TGFβ-SMAD signaling, alongside reduced nuclear pSMAD1/5/8 in cardiac tissues. Compound +/ΔIIA; Smad4+/- mutants exhibit aggravated malformations. IIA enhances BMP-responsive reporter activity in cells in transactivation assays. We propose that IIA supports a positive functional role on SMAD4-dependent signaling, fine-tuning BMP/TGFβ signaling, thereby regulating GATA4 and NKX2-5 activity during second heart field progenitor specification. These findings position IIA procollagen as a key ECM component that integrates BMP/TGFβ signaling with cardiac transcription factors such as NKX2-5, revealing a feedback loop essential for cardiogenesis. Given its role in cardiac development, IIA emerges as a potential congenital heart disease risk factor.
Keywords: cardiac enhancer; extracellular matrix; heart development; transcriptional regulation; type II procollagen.
Conflict of interest statement
Competing interests statement:Mutant mice comprising mutated type II procollagen Alpha-1 US Patent No. 7,645,917 B2, issued on 12 January 2010. Procollagen IIA Deficient Mice. Chinese Patent Application No. 200580024871.6. Chinese Patent No. CN101001948B issued on 24 May 2017.
References
-
- Cripps R. M., Olson E. N., Control of cardiac development by an evolutionarily conserved transcriptional network. Dev. Biol. 246, 14–28 (2002). - PubMed
-
- Nemer G., Nemer M., Regulation of heart development and function through combinatorial interactions of transcription factors. Ann. Med. 33, 604–610 (2001). - PubMed
MeSH terms
Substances
Grants and funding
- ARC1994/Arthritis &Rheumatism Council
- HKU7275/00 M HKU7696/05 M AoE/M 04/04/Research Grants Council, University Grants Committee (ç"究資助局)
- 354400 573705 573732 1074386 1118576 2008743/Federal Government | DHAC | National Health and Medical Research Council (NHMRC)
- 1180905/Federal Government | DHAC | National Health and Medical Research Council (NHMRC)
- 1110751/Federal Government | DHAC | National Health and Medical Research Council (NHMRC)
LinkOut - more resources
Full Text Sources
Miscellaneous